Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us through the company's on-site GMP facility, and she discusses the clinical experience to date. The therapy is already in a phase 3 study in Europe.

Episode metadata supplied by the publisher feed · Published May 1, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

0:00 14:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 14 minutes long.

When was this BiotechTV - News episode published?

This episode was published on May 1, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!